You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》摩通料中資股迎來盈利預測調升 首選萬科、藥明生物及阿里
阿思達克 07-27 14:41
摩根大通發表研究報告指,中國次季GDP表現或好過市場預期,意味著在不確定因素及風險加劇前,可為中資股帶來一波盈利預測調升。

報告指,A股在4月至5月落後於成熟市場後,6月表現有所反彈,MSCI中國指數至今累積上升19.4%,跑贏上升15.8%的MSCI新興市場及升7.5%的成熟市場,滬深300指數亦升21.9%,盈利預測修正將可緩解MSCI中國指數已到極限的估值,並為股市提供短期支撐。

該行預計,目前地緣政治及全球疫情都有升溫風險,中美有兩國大使館關閉,緊張局勢進一步升級,預計中美摩擦將繼續成為焦點,對峙逐步升級,最終或打擊中國經濟的復甦趨勢。

摩通指,業績期過後下半年周期性因素會趨正常化,另看好疫情下消費模式改變,醫療、電商零售及線上遊戲等領域的發展。該行對健康醫療、非必需性消費品、工業及房地產股予「增持」評級,預期政策有所支持,首選萬科(02202.HK)、阿里巴巴(BABA)美股及藥明生物(02269.HK)。對資訊科技、多元化金融、原材料業、必需消費品及通訊服務行業看法「中性」;並建議「減持」能源、公用事業、銀行及保險股。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account